KYNTRA BIO, INC. 8-KCurrent Reports (8-K / ad hoc)

Changes / Accountants

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated August 13, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KYNTRA BIO, INC. Date: August 13, 2026 By: /s/ David DeLucia David DeLucia Senior Vice President and Chief Financial Officer